Ellen van der Aar

800 total citations
22 papers, 342 citations indexed

About

Ellen van der Aar is a scholar working on Rheumatology, Molecular Biology and Oncology. According to data from OpenAlex, Ellen van der Aar has authored 22 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 8 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Ellen van der Aar's work include Osteoarthritis Treatment and Mechanisms (9 papers), Protease and Inhibitor Mechanisms (5 papers) and Sphingolipid Metabolism and Signaling (4 papers). Ellen van der Aar is often cited by papers focused on Osteoarthritis Treatment and Mechanisms (9 papers), Protease and Inhibitor Mechanisms (5 papers) and Sphingolipid Metabolism and Signaling (4 papers). Ellen van der Aar collaborates with scholars based in Belgium, France and Australia. Ellen van der Aar's co-authors include Sonia Dupont, Roland Blanqué, Bertrand Heckmann, Julie Desrivot, Ann Fieuw, H. Deckx, Florence Namour, F. Eckstein, David Amantini and Pierre Deprez and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Ellen van der Aar

21 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen van der Aar Belgium 11 144 96 80 61 46 22 342
Sharad K. Verma United States 12 144 1.0× 66 0.7× 62 0.8× 95 1.6× 24 0.5× 27 400
Kenneth W. Batchelor United States 9 159 1.1× 13 0.1× 111 1.4× 48 0.8× 53 1.2× 12 442
Amy Sutcliffe United Kingdom 6 92 0.6× 20 0.2× 83 1.0× 15 0.2× 29 0.6× 7 327
Manabu Node Japan 7 245 1.7× 13 0.1× 36 0.5× 74 1.2× 104 2.3× 8 424
Consuelo Tudela Spain 9 300 2.1× 48 0.5× 17 0.2× 36 0.6× 21 0.5× 13 484
Magdalena Birker Switzerland 11 133 0.9× 18 0.2× 120 1.5× 34 0.6× 24 0.5× 15 422
Jean‐Michel Luccarini France 11 213 1.5× 12 0.1× 52 0.7× 87 1.4× 40 0.9× 16 471
Zhanzhan Feng China 14 273 1.9× 17 0.2× 38 0.5× 61 1.0× 102 2.2× 19 395
Lina Dobnikar United Kingdom 7 287 2.0× 15 0.2× 63 0.8× 27 0.4× 19 0.4× 10 461
James Gifford United States 5 101 0.7× 46 0.5× 22 0.3× 46 0.8× 74 1.6× 8 341

Countries citing papers authored by Ellen van der Aar

Since Specialization
Citations

This map shows the geographic impact of Ellen van der Aar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen van der Aar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen van der Aar more than expected).

Fields of papers citing papers by Ellen van der Aar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen van der Aar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen van der Aar. The network helps show where Ellen van der Aar may publish in the future.

Co-authorship network of co-authors of Ellen van der Aar

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen van der Aar. A scholar is included among the top collaborators of Ellen van der Aar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen van der Aar. Ellen van der Aar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dulos, John, et al.. (2025). ADAMTS-5 inhibition reduces muscle inflammation and fibrosis and improves function in mouse models of Duchenne muscular dystrophy. Science Translational Medicine. 17(803). eado2112–eado2112.
2.
Schnitzer, Thomas J., María Pueyo, H. Deckx, et al.. (2023). Evaluation of S201086/GLPG1972, an ADAMTS-5 inhibitor, for the treatment of knee osteoarthritis in ROCCELLA: a phase 2 randomized clinical trial. Osteoarthritis and Cartilage. 31(7). 985–994. 26 indexed citations
3.
Schnitzer, Thomas J., María Pueyo, H. Deckx, et al.. (2021). Efficacy and safety of s201086/GLPG1972, an ADAMTS-5 inhibitor, in patients with knee osteoarthritis: roccella, a 52-week, randomized, double-blind, dose-ranging phase 2 study. Osteoarthritis and Cartilage. 29. S264–S264. 5 indexed citations
4.
Deckx, H., Ellen van der Aar, María Pueyo, et al.. (2021). The design of a randomized, placebo-controlled, dose-ranging trial to investigate the efficacy and safety of the ADAMTS-5 inhibitor S201086/GLPG1972 in knee osteoarthritis. SHILAP Revista de lepidopterología. 3(4). 100209–100209. 16 indexed citations
5.
Little, Christopher B., Margaret M. Smith, Patrick Mollat, et al.. (2021). Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5. Osteoarthritis and Cartilage. 30(2). 291–301. 22 indexed citations
6.
Aar, Ellen van der, H. Deckx, Sonia Dupont, et al.. (2021). Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS‐5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip. Clinical Pharmacology in Drug Development. 11(1). 112–122. 17 indexed citations
7.
Colapietro, Alessandro, Giovanni Luca Gravina, Irene Fasciani, et al.. (2020). Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines In Vitro and In Vivo. Journal of Oncology. 2020. 1–16. 10 indexed citations
8.
Taneja, Amit, Julie Desrivot, Paul M. Diderichsen, et al.. (2019). Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis. Clinical Pharmacokinetics. 58(9). 1175–1191. 10 indexed citations
9.
Aar, Ellen van der, Julie Desrivot, Sonia Dupont, et al.. (2019). Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials. The Journal of Clinical Pharmacology. 59(10). 1366–1378. 34 indexed citations
10.
Lepescheux, L., Monica Borgonovi, Patrick Mollat, et al.. (2018). OP0258 Efficacy of the highly selective adamts-5 inhibitor glpg1972 in the rat meniscectomy model. Annals of the Rheumatic Diseases. 77. 178–178. 3 indexed citations
11.
12.
Little, Christopher B., Roland Blanqué, Patrick Mollat, et al.. (2017). GLPG1972: a potent, selective, orally available adamts-5 inhibitor for the treatment of OA. Osteoarthritis and Cartilage. 25. S58–S59. 13 indexed citations
13.
Clément-Lacroix, Philippe, Christopher B. Little, Roland Blanqué, et al.. (2017). OP0180 Pharmacological characterization of the ADAMTS-5 inhibitor GLPG1972: an oral anti-catabolic agent for the treatment of osteoarthritis. Annals of the Rheumatic Diseases. 76. 126–126. 1 indexed citations
14.
Ongenaert, Maté, Sonia Dupont, Roland Blanqué, et al.. (2016). Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF. OA4540–OA4540. 8 indexed citations
15.
Aar, Ellen van der, Julie Desrivot, Sonia Dupont, et al.. (2015). Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD. OA484–OA484. 6 indexed citations
16.
Blanqué, Roland, Nicolas Desroy, Sonia Dupont, et al.. (2015). Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment. PA2129–PA2129. 5 indexed citations
17.
Pujuguet, Philippe, Ellen van der Aar, Reginald Brys, et al.. (2014). Abstract 1753: GLPG1790: The first Ephrin (EPH) receptor tyrosine kinase inhibitor for the treatment of triple negative breast cancer. Cancer Research. 74(19_Supplement). 1753–1753. 3 indexed citations
18.
Fisher, Matthew J., Vanessa Barth, Joseph M. Gruber, et al.. (2012). 3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity. Bioorganic & Medicinal Chemistry Letters. 22(7). 2514–2517. 21 indexed citations
19.
Nique, F., Nicolas Triballeau, Christophe Peixoto, et al.. (2012). Identification of a 4-(Hydroxymethyl)diarylhydantoin as a Selective Androgen Receptor Modulator. Journal of Medicinal Chemistry. 55(19). 8236–8247. 48 indexed citations
20.
Mijatovic, Tatjana, Tina Mahieu, Céline Bruyère, et al.. (2008). UNBS5162, a Novel Naphthalimide That Decreases CXCL Chemokine Expression in Experimental Prostate Cancers. Neoplasia. 10(6). 573–586. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sharad K. Verma Breakdown of academic impact, for papers by Kenneth W. Batchelor Breakdown of academic impact, for papers by Amy Sutcliffe Breakdown of academic impact, for papers by Manabu Node Breakdown of academic impact, for papers by Consuelo Tudela Breakdown of academic impact, for papers by Magdalena Birker Breakdown of academic impact, for papers by Jean‐Michel Luccarini Breakdown of academic impact, for papers by Zhanzhan Feng Breakdown of academic impact, for papers by Lina Dobnikar Breakdown of academic impact, for papers by James Gifford
Rankless by CCL
2026